DoD Lung Cancer Research Program funding opportunities for FY23

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

Montefiore Einstein Comprehensive Cancer Center announced that its lung cancer team has been recognized by the International Association for the Study of Lung Cancer for delivering outstanding care. The announcement was made during the IASLC annual meeting in Barcelona.

October 03, 2025

Vol.51 No.36

Clinical Roundup

American Lung Association launches campaign to address barriers to lung cancer screening and care

The American Lung Association launched a campaign to raise awareness about lung cancer screening and biomarker testing, shaped by the voices of people diagnosed with lung cancer and their caregivers across the country.

October 03, 2025

Vol.51 No.36

Drugs & Targets

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

FDA has granted a approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a maintenance treatment for adults with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.

October 03, 2025

Vol.51 No.36

Cancer Policy

Bhattacharya: New grant review criterion is “not political”

NIH’s new “unified grant funding policy,” is “not political,” NIH Director Jay Bhattacharya said during his remarks at Research!America’s annual National Health Research Forum Sept. 17.

September 26, 2025

Vol.51 No.35

By Jacquelyn Cobb

Funding Opportunities

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation.

September 26, 2025

Vol.51 No.35

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.

September 19, 2025

Vol.51 No.34

By Paul Goldberg

DoD Lung Cancer Research Program funding opportunities for FY23

YOU MAY BE INTERESTED IN

Montefiore Einstein Comprehensive Cancer Center’s lung cancer team earns international recognition

American Lung Association launches campaign to address barriers to lung cancer screening and care

FDA approves Zepzelca + Tecentriq combination as first-line maintenance therapy for ES-SCLC

Bhattacharya: New grant review criterion is “not political”

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

NCI is “really, really sturdy” and won’t break, former directors Ned Sharpless and Kim Rathmell say at UNC Lineberger symposium

Renew today!

Subscriber content

Never miss an issue!

Login